Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 4/20 | 0.34 |
| ▸ | APOL1 | O14791 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412212 | 0.84 | TUBB4A (0.47) | ALDH1A1LMNA | |
| SCHEMBL5662948 | 0.80 | PTGS2 (0.39) | MAP2PTGS2FEN1ALDH1A1 | |
| SCHEMBL4550554 | 0.78 | MAP2 (0.38) | MAP2FEN1LMNA | |
| SCHEMBL4540828 | 0.76 | MAP2 (0.45) | MAP2PTGS2FEN1 | |
| SCHEMBL30039524 | 0.73 | TUBB4A (0.54) | MAP2FEN1ALDH1A1LMNA | |
| SCHEMBL4551243 | 0.72 | MAP2 (0.38) | MAP2PTGS2FEN1 | |
| SCHEMBL4551399 | 0.72 | TUBB4A (0.42) | MAP2FEN1ALDH1A1 | |
| SCHEMBL4398675 | 0.72 | MAP2 (0.36) | MAP2PTGS2FEN1ALDH1A1LMNA | |
| SCHEMBL3583102 | 0.71 | SLC1A3 (0.34) | FEN1ALDH1A1LMNA | |
| SCHEMBL4329236 | 0.71 | TUBB4A (0.52) | MAP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390029-B1 | PHENYLINDOLES FOR THE TREATMENT OF HIV | IDENIX CAYMAN LTD (KY) | 2009-12-16 | — | — | EP | disclosed |
| US-20070293668-A1 | Phenylindoles for the treatment of HIV | LACOLLA PAULO | 2007-12-20 | — | — | US | disclosed |
| EP-1390029-A4 | PHENYLINDOLES FOR THE TREATMENT OF HIV | IDENIX CAYMAN LTD (KY) | 2005-11-30 | — | — | EP | disclosed |
| US-20040180888-A1 | Phenylindoles for the treatment of HIV | IDENIX PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| US-6710068-B2 | PHENYLSULFONYLINODLES USEFUL FOR THE TREATMENT OF HIV IN HUMANS AND OTHER HOST ANIMALS | IDENIX PHARMACEUTICALS, INC. | 2004-03-23 | — | — | US | disclosed |
| EP-1390029-A1 | PHENYLINDOLES FOR THE TREATMENT OF HIV | Idenix (Cayman) Limited (KY) | 2004-02-25 | — | — | EP | disclosed |
| US-20020193415-A1 | Phenylindoles for the treatment of HIV | IDENIX PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | disclosed |
| WO-2002083126-A1 | PHENYLINDOLES FOR THE TREATMENT OF HIV | IDENIX (CAYMAN) LIMITED (KY) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293668-A1 | Phenylindoles for the treatment of HIV | DUT, NQO1, ENTPD5 | MAP2 1309/4885PTGS2 2710/4885FEN1 2039/4885 |
| US-20020193415-A1 | Phenylindoles for the treatment of HIV | DUT, NQO1, ENTPD5 | MAP2 1309/4885PTGS2 2710/4885FEN1 2039/4885 |
| US-20040180888-A1 | Phenylindoles for the treatment of HIV | DUT, NQO1, ENTPD5 | MAP2 1309/4885PTGS2 2710/4885FEN1 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.